Clinical Trials Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Phase (Phase I, Phase II, Phase III, Phase IV); Study Design (Interventional, Observational, Expanded access); Indication (Autoimmune/inflammation, Pain management, Oncology, CNS condition, Diabetes, Obesity, Cardiovascular, Others) and Geography
A clinical trial is a research study, where a group of people is given a test or treatment. Clinical trials study the safety and efficacy of tests and treatments. If the test or treatment is safe and meets regulatory requirements, then it is approved as a standard of care.
The Clinical trial market is anticipated to grow in the forecast, owing to the globalization of clinical trials, development of new treatments such as personalized medicine and increasing prevalence of infectious disease and new disease cases. In addition, increasing investments to develop new healthcare products is expected to offer significant growth opportunities in the market during the forecast period.
The "Global Clinical Trial market Analysis to 2027" is a specialized and in-depth study of the medical device industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the Clinical trial market with detailed market segmentation by phase, study design, indication and geography. The global Clinical trial market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Clinical trial market players and offers key trends and opportunities in the market.
The global Clinical trial market is segmented on the basis of phase, study design, indication. Based on phase, the market is segmented as, phase I, phase II, phase III and phase IV. Based on the study design, the market is segmented into interventional, observational and expanded access. Based on indication, the market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular and others.
Get more information on this report :
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Clinical trial market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Clinical trial market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Clinical trial market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Clinical trial market in these regions.
Get more information on this report :
The reports cover key developments in the Clinical trial market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others, such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved the way for the expansion of business and customer base of market players. The market payers from Clinical trial market are anticipated to lucrative growth opportunities in the future with the rising demand for Clinical trial market in the global market. Below mentioned is the list of few companies engaged in the Clinical trial market.
The report also includes the profiles of key Clinical trial market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of the last 3 years, key development in the past five years.
Parexel International Corporation
Charles River Laboratories
Chiltern International Ltd
PRA Health Sciences
Wuxi AppTec Inc
Pharmaceutical Product Development, LLC
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Get more information on this report :
TABLE OF CONTENTS
1. INTRODUCTION 1.1. SCOPE OF THE STUDY 1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE 1.3. MARKET SEGMENTATION 1.3.1 Clinical Trials - By Phase 1.3.2 Clinical Trials - By Study Design 1.3.3 Clinical Trials - By Indication 1.3.4 Clinical Trials - By Region 126.96.36.199 By Country 2. KEY TAKEAWAYS 3. RESEARCH METHODOLOGY 4. CLINICAL TRIALS LANDSCAPE 4.1. OVERVIEW 4.2. PEST ANALYSIS 4.2.1 North America - Pest Analysis 4.2.2 Europe - Pest Analysis 4.2.3 Asia-Pacific - Pest Analysis 4.2.4 Middle East and Africa - Pest Analysis 4.2.5 South and Central America - Pest Analysis 4.3. EXPERT OPINIONS 5. CLINICAL TRIALS - KEY MARKET DYNAMICS 5.1. KEY MARKET DRIVERS 5.2. KEY MARKET RESTRAINTS 5.3. KEY MARKET OPPORTUNITIES 5.4. FUTURE TRENDS 5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC 6. CLINICAL TRIALS - GLOBAL MARKET ANALYSIS 6.1. CLINICAL TRIALS - GLOBAL MARKET OVERVIEW 6.2. CLINICAL TRIALS - GLOBAL MARKET AND FORECAST TO 2027 6.3. MARKET POSITIONING/MARKET SHARE 7. CLINICAL TRIALS - REVENUE AND FORECASTS TO 2027 - PHASE 7.1. OVERVIEW 7.2. PHASE MARKET FORECASTS AND ANALYSIS 7.3. PHASE I 7.3.1. Overview 7.3.2. Phase I Market Forecast and Analysis 7.4. PHASE II 7.4.1. Overview 7.4.2. Phase II Market Forecast and Analysis 7.5. PHASE III 7.5.1. Overview 7.5.2. Phase III Market Forecast and Analysis 7.6. PHASE IV 7.6.1. Overview 7.6.2. Phase IV Market Forecast and Analysis 8. CLINICAL TRIALS - REVENUE AND FORECASTS TO 2027 - STUDY DESIGN 8.1. OVERVIEW 8.2. STUDY DESIGN MARKET FORECASTS AND ANALYSIS 8.3. INTERVENTIONAL 8.3.1. Overview 8.3.2. Interventional Market Forecast and Analysis 8.4. OBSERVATIONAL 8.4.1. Overview 8.4.2. Observational Market Forecast and Analysis 8.5. EXPANDED ACCESS 8.5.1. Overview 8.5.2. Expanded access Market Forecast and Analysis 9. CLINICAL TRIALS - REVENUE AND FORECASTS TO 2027 - INDICATION 9.1. OVERVIEW 9.2. INDICATION MARKET FORECASTS AND ANALYSIS 9.3. AUTOIMMUNE/INFLAMMATION 9.3.1. Overview 9.3.2. Autoimmune/inflammation Market Forecast and Analysis 9.4. PAIN MANAGEMENT 9.4.1. Overview 9.4.2. Pain management Market Forecast and Analysis 9.5. ONCOLOGY 9.5.1. Overview 9.5.2. Oncology Market Forecast and Analysis 9.6. CNS CONDITION 9.6.1. Overview 9.6.2. CNS condition Market Forecast and Analysis 9.7. DIABETES 9.7.1. Overview 9.7.2. Diabetes Market Forecast and Analysis 9.8. OBESITY 9.8.1. Overview 9.8.2. Obesity Market Forecast and Analysis 9.9. CARDIOVASCULAR 9.9.1. Overview 9.9.2. Cardiovascular Market Forecast and Analysis 9.10. OTHERS 9.10.1. Overview 9.10.2. Others Market Forecast and Analysis 10. CLINICAL TRIALS REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS 10.1. NORTH AMERICA 10.1.1 North America Clinical Trials Overview 10.1.2 North America Clinical Trials Forecasts and Analysis 10.1.3 North America Clinical Trials Forecasts and Analysis - By Phase 10.1.4 North America Clinical Trials Forecasts and Analysis - By Study Design 10.1.5 North America Clinical Trials Forecasts and Analysis - By Indication 10.1.6 North America Clinical Trials Forecasts and Analysis - By Countries 10.1.6.1 United States Clinical Trials 10.1.6.1.1 United States Clinical Trials by Phase 10.1.6.1.2 United States Clinical Trials by Study Design 10.1.6.1.3 United States Clinical Trials by Indication 10.1.6.2 Canada Clinical Trials 10.1.6.2.1 Canada Clinical Trials by Phase 10.1.6.2.2 Canada Clinical Trials by Study Design 10.1.6.2.3 Canada Clinical Trials by Indication 10.1.6.3 Mexico Clinical Trials 10.1.6.3.1 Mexico Clinical Trials by Phase 10.1.6.3.2 Mexico Clinical Trials by Study Design 10.1.6.3.3 Mexico Clinical Trials by Indication 10.2. EUROPE 10.2.1 Europe Clinical Trials Overview 10.2.2 Europe Clinical Trials Forecasts and Analysis 10.2.3 Europe Clinical Trials Forecasts and Analysis - By Phase 10.2.4 Europe Clinical Trials Forecasts and Analysis - By Study Design 10.2.5 Europe Clinical Trials Forecasts and Analysis - By Indication 10.2.6 Europe Clinical Trials Forecasts and Analysis - By Countries 10.2.6.1 Germany Clinical Trials 10.2.6.1.1 Germany Clinical Trials by Phase 10.2.6.1.2 Germany Clinical Trials by Study Design 10.2.6.1.3 Germany Clinical Trials by Indication 10.2.6.2 France Clinical Trials 10.2.6.2.1 France Clinical Trials by Phase 10.2.6.2.2 France Clinical Trials by Study Design 10.2.6.2.3 France Clinical Trials by Indication 10.2.6.3 Italy Clinical Trials 10.2.6.3.1 Italy Clinical Trials by Phase 10.2.6.3.2 Italy Clinical Trials by Study Design 10.2.6.3.3 Italy Clinical Trials by Indication 10.2.6.4 Spain Clinical Trials 10.2.6.4.1 Spain Clinical Trials by Phase 10.2.6.4.2 Spain Clinical Trials by Study Design 10.2.6.4.3 Spain Clinical Trials by Indication 10.2.6.5 United Kingdom Clinical Trials 10.2.6.5.1 United Kingdom Clinical Trials by Phase 10.2.6.5.2 United Kingdom Clinical Trials by Study Design 10.2.6.5.3 United Kingdom Clinical Trials by Indication 10.3. ASIA-PACIFIC 10.3.1 Asia-Pacific Clinical Trials Overview 10.3.2 Asia-Pacific Clinical Trials Forecasts and Analysis 10.3.3 Asia-Pacific Clinical Trials Forecasts and Analysis - By Phase 10.3.4 Asia-Pacific Clinical Trials Forecasts and Analysis - By Study Design 10.3.5 Asia-Pacific Clinical Trials Forecasts and Analysis - By Indication 10.3.6 Asia-Pacific Clinical Trials Forecasts and Analysis - By Countries 10.3.6.1 Australia Clinical Trials 10.3.6.1.1 Australia Clinical Trials by Phase 10.3.6.1.2 Australia Clinical Trials by Study Design 10.3.6.1.3 Australia Clinical Trials by Indication 10.3.6.2 China Clinical Trials 10.3.6.2.1 China Clinical Trials by Phase 10.3.6.2.2 China Clinical Trials by Study Design 10.3.6.2.3 China Clinical Trials by Indication 10.3.6.3 India Clinical Trials 10.3.6.3.1 India Clinical Trials by Phase 10.3.6.3.2 India Clinical Trials by Study Design 10.3.6.3.3 India Clinical Trials by Indication 10.3.6.4 Japan Clinical Trials 10.3.6.4.1 Japan Clinical Trials by Phase 10.3.6.4.2 Japan Clinical Trials by Study Design 10.3.6.4.3 Japan Clinical Trials by Indication 10.3.6.5 South Korea Clinical Trials 10.3.6.5.1 South Korea Clinical Trials by Phase 10.3.6.5.2 South Korea Clinical Trials by Study Design 10.3.6.5.3 South Korea Clinical Trials by Indication 10.4. MIDDLE EAST AND AFRICA 10.4.1 Middle East and Africa Clinical Trials Overview 10.4.2 Middle East and Africa Clinical Trials Forecasts and Analysis 10.4.3 Middle East and Africa Clinical Trials Forecasts and Analysis - By Phase 10.4.4 Middle East and Africa Clinical Trials Forecasts and Analysis - By Study Design 10.4.5 Middle East and Africa Clinical Trials Forecasts and Analysis - By Indication 10.4.6 Middle East and Africa Clinical Trials Forecasts and Analysis - By Countries 10.4.6.1 South Africa Clinical Trials 10.4.6.1.1 South Africa Clinical Trials by Phase 10.4.6.1.2 South Africa Clinical Trials by Study Design 10.4.6.1.3 South Africa Clinical Trials by Indication 10.4.6.2 Saudi Arabia Clinical Trials 10.4.6.2.1 Saudi Arabia Clinical Trials by Phase 10.4.6.2.2 Saudi Arabia Clinical Trials by Study Design 10.4.6.2.3 Saudi Arabia Clinical Trials by Indication 10.4.6.3 U.A.E Clinical Trials 10.4.6.3.1 U.A.E Clinical Trials by Phase 10.4.6.3.2 U.A.E Clinical Trials by Study Design 10.4.6.3.3 U.A.E Clinical Trials by Indication 10.5. SOUTH AND CENTRAL AMERICA 10.5.1 South and Central America Clinical Trials Overview 10.5.2 South and Central America Clinical Trials Forecasts and Analysis 10.5.3 South and Central America Clinical Trials Forecasts and Analysis - By Phase 10.5.4 South and Central America Clinical Trials Forecasts and Analysis - By Study Design 10.5.5 South and Central America Clinical Trials Forecasts and Analysis - By Indication 10.5.6 South and Central America Clinical Trials Forecasts and Analysis - By Countries 10.5.6.1 Brazil Clinical Trials 10.5.6.1.1 Brazil Clinical Trials by Phase 10.5.6.1.2 Brazil Clinical Trials by Study Design 10.5.6.1.3 Brazil Clinical Trials by Indication 10.5.6.2 Argentina Clinical Trials 10.5.6.2.1 Argentina Clinical Trials by Phase 10.5.6.2.2 Argentina Clinical Trials by Study Design 10.5.6.2.3 Argentina Clinical Trials by Indication 11. INDUSTRY LANDSCAPE 11.1. MERGERS AND ACQUISITIONS 11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES 11.3. NEW PRODUCT LAUNCHES 11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS 12. CLINICAL TRIALS, KEY COMPANY PROFILES 12.1. IQVIA 12.1.1. Key Facts 12.1.2. Business Description 12.1.3. Products and Services 12.1.4. Financial Overview 12.1.5. SWOT Analysis 12.1.6. Key Developments 12.2. PAREXEL INTERNATIONAL CORPORATION 12.2.1. Key Facts 12.2.2. Business Description 12.2.3. Products and Services 12.2.4. Financial Overview 12.2.5. SWOT Analysis 12.2.6. Key Developments 12.3. PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC 12.3.1. Key Facts 12.3.2. Business Description 12.3.3. Products and Services 12.3.4. Financial Overview 12.3.5. SWOT Analysis 12.3.6. Key Developments 12.4. CHARLES RIVER LABORATORY 12.4.1. Key Facts 12.4.2. Business Description 12.4.3. Products and Services 12.4.4. Financial Overview 12.4.5. SWOT Analysis 12.4.6. Key Developments 12.5. ICON PLC 12.5.1. Key Facts 12.5.2. Business Description 12.5.3. Products and Services 12.5.4. Financial Overview 12.5.5. SWOT Analysis 12.5.6. Key Developments 12.6. WUXI APPTEC INC 12.6.1. Key Facts 12.6.2. Business Description 12.6.3. Products and Services 12.6.4. Financial Overview 12.6.5. SWOT Analysis 12.6.6. Key Developments 12.7. PRA HEALTH SCIENCES 12.7.1. Key Facts 12.7.2. Business Description 12.7.3. Products and Services 12.7.4. Financial Overview 12.7.5. SWOT Analysis 12.7.6. Key Developments 12.8. SGS SA 12.8.1. Key Facts 12.8.2. Business Description 12.8.3. Products and Services 12.8.4. Financial Overview 12.8.5. SWOT Analysis 12.8.6. Key Developments 12.9. SYNEOS HEALTH 12.9.1. Key Facts 12.9.2. Business Description 12.9.3. Products and Services 12.9.4. Financial Overview 12.9.5. SWOT Analysis 12.9.6. Key Developments 12.10. CHILTERN INTERNATIONAL LTD 12.10.1. Key Facts 12.10.2. Business Description 12.10.3. Products and Services 12.10.4. Financial Overview 12.10.5. SWOT Analysis 12.10.6. Key Developments 13. APPENDIX 13.1. ABOUT THE INSIGHT PARTNERS 13.2. GLOSSARY OF TERMS